Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1981-5-13
|
pubmed:abstractText |
By a newly developed technique, we have modified H-2k-negative cells in such a way as to render them capable of elicitation of anti-H-2 CTL. Purified H-2Kk and/or partially purified Iak glycoproteins were incorporated into lipid vesicles that contained the hemagglutinin-neuraminidase (HN) glycoprotein and the fusion (F) glycoprotein of Sendai virus. These lipid vesicles were incubated with H-2-negative tumor cells (R1-) in a manner that resulted in rendering these cells capable of eliciting anti-H-2Kk CTL. The presence of Iak on the surface of the modified stimulator cell had a significant effect on the proportion of anti-H-2Kk CTL possessing a particular Lyt phenotype. Primary effector cells elicited by an H-2Kk-Iak difference were primarily Lyt 1-, 2+, whereas primary anti-H-2Kk CTL elicited by an H-2Kk difference alone were predominantly Lyt 1+, 2+.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
126
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1485-8
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:6970778-Animals,
pubmed-meshheading:6970778-Antigens,
pubmed-meshheading:6970778-Cytotoxicity, Immunologic,
pubmed-meshheading:6970778-Female,
pubmed-meshheading:6970778-H-2 Antigens,
pubmed-meshheading:6970778-Histocompatibility Antigens Class II,
pubmed-meshheading:6970778-Immune Sera,
pubmed-meshheading:6970778-Lymphoma,
pubmed-meshheading:6970778-Male,
pubmed-meshheading:6970778-Mice,
pubmed-meshheading:6970778-Mice, Inbred BALB C,
pubmed-meshheading:6970778-Phenotype,
pubmed-meshheading:6970778-Spleen,
pubmed-meshheading:6970778-T-Lymphocytes
|
pubmed:year |
1981
|
pubmed:articleTitle |
Elicitation of anti-H-2 cytotoxic T lymphocytes with antigen-modified H-2 negative stimulator cells.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|